786 related articles for article (PubMed ID: 17964036)
1. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
[TBL] [Abstract][Full Text] [Related]
2. Apolipoproteins as markers and managers of coronary risk.
Chan DC; Watts GF
QJM; 2006 May; 99(5):277-87. PubMed ID: 16504986
[TBL] [Abstract][Full Text] [Related]
3. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
[TBL] [Abstract][Full Text] [Related]
4. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?
Sniderman A; McQueen M; Contois J; Williams K; Furberg CD
J Clin Lipidol; 2010; 4(3):152-5. PubMed ID: 21122647
[TBL] [Abstract][Full Text] [Related]
5. The association between serum apolipoprotein A-I and apolipoprotein B and the severity of angiographical coronary artery disease.
Khadem-Ansari MH; Rasmi Y; Rahimi-Pour A; Jafarzadeh M
Singapore Med J; 2009 Jun; 50(6):610-3. PubMed ID: 19551315
[TBL] [Abstract][Full Text] [Related]
6. [Role of small dense low-density lipoprotein in coronary artery disease patients with normal plasma cholesterol levels].
Koba S; Hirano T; Sakaue T; Sakai K; Kondo T; Yorozuya M; Suzuki H; Murakami M; Katagiri T
J Cardiol; 2000 Dec; 36(6):371-8. PubMed ID: 11190580
[TBL] [Abstract][Full Text] [Related]
7. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy.
Walldius G; Jungner I
Nutr Metab Cardiovasc Dis; 2007 Oct; 17(8):565-71. PubMed ID: 17631989
[TBL] [Abstract][Full Text] [Related]
8. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
Otvos JD; Collins D; Freedman DS; Shalaurova I; Schaefer EJ; McNamara JR; Bloomfield HE; Robins SJ
Circulation; 2006 Mar; 113(12):1556-63. PubMed ID: 16534013
[TBL] [Abstract][Full Text] [Related]
9. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment.
Andrikoula M; McDowell IF
Diabetes Obes Metab; 2008 Apr; 10(4):271-8. PubMed ID: 18333887
[TBL] [Abstract][Full Text] [Related]
10. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease.
Sniderman AD; Jungner I; Holme I; Aastveit A; Walldius G
J Intern Med; 2006 May; 259(5):455-61. PubMed ID: 16629851
[TBL] [Abstract][Full Text] [Related]
11. Genetic contributions to quantitative lipoprotein traits associated with coronary artery disease: analysis of a large pedigree from the Bogalusa Heart Study.
Heiba IM; DeMeester CA; Xia YR; Diep A; George VT; Amos CI; Srinivasan SR; Berenson GS; Elston RC; Lusis AJ
Am J Med Genet; 1993 Nov; 47(6):875-83. PubMed ID: 8279486
[TBL] [Abstract][Full Text] [Related]
12. LDL molecular size as risk factor in coronary artery disease.
Kozma L; Fodor J; Chockalingam A; Sussex B
Acta Med Hung; 1992-1993; 49(1-2):65-77. PubMed ID: 1296188
[TBL] [Abstract][Full Text] [Related]
13. [Small dense LDL concentration is closely associated with serum apolipoprotein B, comparisons of non-LDL cholesterol or LDL cholesterol].
Hayashi T; Hirano T; Shiobara T; Suguro T; Adachi M
Rinsho Byori; 2006 Jun; 54(6):569-75. PubMed ID: 16872005
[TBL] [Abstract][Full Text] [Related]
14. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease.
Miller M; Ginsberg HN; Schaefer EJ
Am J Cardiol; 2008 Apr; 101(7):1003-8. PubMed ID: 18359322
[TBL] [Abstract][Full Text] [Related]
15. Effects of short- and long-term growth hormone replacement on lipoprotein composition and on very-low-density lipoprotein and low-density lipoprotein apolipoprotein B100 kinetics in growth hormone-deficient hypopituitary subjects.
Kearney T; de Gallegos CN; Proudler A; Parker K; Anayaoku V; Bannister P; Venkatesan S; Johnston DG
Metabolism; 2003 Jan; 52(1):50-9. PubMed ID: 12524662
[TBL] [Abstract][Full Text] [Related]
16. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
17. [Serum apolipoprotein B is superior to LDL-cholesterol level in predicting incident coronary disease among Turks].
Onat A; Ozhan H; Can G; Hergenç G; Karabulut A; Albayrak S
Anadolu Kardiyol Derg; 2007 Jun; 7(2):128-33. PubMed ID: 17513206
[TBL] [Abstract][Full Text] [Related]
18. Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women.
Matthan NR; Welty FK; Barrett PH; Harausz C; Dolnikowski GG; Parks JS; Eckel RH; Schaefer EJ; Lichtenstein AH
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1092-7. PubMed ID: 15087307
[TBL] [Abstract][Full Text] [Related]
19. Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?
Jungner I; Sniderman AD; Furberg C; Aastveit AH; Holme I; Walldius G
Am J Cardiol; 2006 Apr; 97(7):943-6. PubMed ID: 16563891
[TBL] [Abstract][Full Text] [Related]
20. Advanced lipoprotein testing: recommendations based on current evidence.
Lau JF; Smith DA
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):1-31. PubMed ID: 19217510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
